FORMULATION OPTIMIZATION AND EVALUATION OF FLURBIPROFEN EMULGEL
Objective: The objective of the present study was to formulate flurbiprofen (FLB) emulgel, evaluation of the formulations and the selection of an optimized formulation through in vitro drug release and drug content studies. Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) requiring frequent administration and its chronic intake can lead to systemic side effects like gastric irritation and GI bleeding. The development of a dermal drug delivery system can overcome these side effects.
Methods: The emulgel formulations were produced using different combinations of oil and emulsifying agents. Carbopol 940 was used as a gelling agent. The prepared emulgels were evaluated for general appearance, pH, spreadability, extrudability, drug content, in vitro drug release, average globule size and viscosity.
Results: Optimized formulation F7 showed a better in vitro drug release compared to the marketed gel preparation. The stability study for the optimized formulation was carried out at 25 °C/60 % RH for 3 mo and the emulgel was found to be stable concerning the physical appearance, pH and drug content.
Conclusion: The study revolved around the formulation of emulgel containing Flurbiprofen for dermal delivery of the drug. Emulgel was formulated with the purpose to enhance the permeation of poorly water-soluble drug FLB. The study concluded that the optimized emulgel containing FLB exhibited better in vitro drug release profile compared to the marketed formulation.
2. Rudrangi S, Kaialy W, Ghori M, Trivedi V, Snowden M, Alexander B. Solid-state flurbiprofen and methyl-?-cyclodextrin inclusion complexes prepared using a single-step, organic solvent-free supercritical fluid process. Eur J Pharm Biopharm 2016;104:164-70.
3. Paliwal S, Tilak A, Sharma J, Dave V, Sharma S, Verma K. et al. Flurbiprofen-loaded ethanolic liposome particles for biomedical applications. J Microbiol Methods 2019;161:18-27.
4. Tiwari R, Tiwari G. Dissolution is modulating mechanism of flurbiprofen solid dispersions: characterization, physical stability and in vivo performance: formulation considerations and optimization study. Pharm Methods 2017;8:127-35.
5. Sarfaraz M, Sharma S. Formulation and evaluation of flurbiprofen fast disintegrating tablets using natural disintegrants. Asian J Pharm Clin Res 2016;9:247-54.
6. Redkar M, Patil S, Rukari T. Emulgel: a modern tool for topical drug delivery. World J Pharm Res 2019;8:586-97.
7. Ajazuddin, Alexander A, Khichariya A, Gupta S, Patel R, Giri T, et al. Recent expansions in an emergent novel drug delivery technology: Emulgel. J Controlled Release 2013;171:122-32.
8. Khunt D, Mishra A, Shah D. Formulation design and development of piroxicam emulgel. Int J PharmTech Res 2012;4:1332-44.
9. Bhanu VP, Shanmugam V, Lakshmi PK. Development and optimization of novel diclofenac emulgel for topical drug delivery. Int J Contemp Pediatr 2020;9:1-4.
10. Bhattacharya S, Prajapati B. Formulation and optimization of celcoxib nanoemulgel. Asian J Pharm Clin Res 2017;10:353-65.
11. Joshi Baibhav, Singh Gurpreet, Rana AC, Saini Seema. Development and characterization of clarithromycin emulgel for topical delivery. Int J Drug Dev Res 2012;4:310-23.
12. Jain A, Gautam S, Gupta Y, Khambete H, Jain S. Development and characterization of ketoconazole emulgel for topical drug delivery. Der Pharm Sin 2010;1:221-31.
13. MR, VS, RN, KM. Formulation and in vitro evaluation of ciprofloxacin loaded topical emulgel. Int J Pharmacol Clin Sci 2016;1:237-41.
14. Sah S, Badola A, Mukhopadhyay S. Development and evaluation of tioconazole loaded emulgel. Int J Appl Pharm 2017;9:83-90.
15. Vani Y, Reddy C. Formulation and in vitro evaluation of piroxicam emulgel. Int J Pharm Sci Drug Res 2018;10:227-32.
16. Mohamed M. Optimization of chlorphenesin emulgel formulation. AAPS J 2004;6:81-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.